Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$15.43 USD
+0.47 (3.14%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.42 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.43 USD
+0.47 (3.14%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.42 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
by Zacks Equity Research
Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
by Zacks Equity Research
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
by Zacks Equity Research
Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
by Sundeep Ganoria
Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.
Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 123.4% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 163.8% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 13.25% and 88.33%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in Denali Therapeutics Inc. (DNLI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.33% and 9.21%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Orchard Therapeutics PLC Sponsored ADR (ORTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues
by Zacks Equity Research
Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.
Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 251.16% and 2,502.86%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Denali (DNLI) Provides Update on Hunter Syndrome Study
by Zacks Equity Research
Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome).
Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?
by Zacks Equity Research
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
by Zacks Equity Research
Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.68% and 15.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?